This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Litigation Settlements, Data Compliance Reviews, And Clinical Trials Pave Way For Solid Footing In Healthcare - Research Report On Pfizer, Merck, Bristol-Myers Squibb, Keryx And Pacira Pharmaceuticals

Bristol-Myers Squibb Company Research Report

On June 12, 2013, Bristol-Myers Squibb Company (Bristol Myers Squibb) and AstraZeneca announced that they will continue to work with health authorities and scientific experts around the world to closely monitor the use of our GLP-1 receptor agonist and DPP-4 inhibitor through comprehensive surveillance programs to ensure patients and physicians have a clear understanding of the risk/benefit profile of these medications. This announcement came after the American Diabetes Association (ADA) called for incretin-based therapies manufacturers to make available the patient-level data from clinical trials for an independent analysis of pancreatic safety. The Full Research Report on Bristol-Myers Squibb Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [ http://www.WSReports.com/r/full_research_report/88a2_BMY]

--

Keryx Biopharmaceuticals Inc. Research Report

On June 3, 2013, Keryx Biopharmaceuticals, Inc. (Keryx) announced the presentation of updated efficacy and safety data from the Phase 3 long-term clinical trial of ZenerexZerenex (ferric citrate). Based on the efficacy results, Keryx determined that Zerenex is an efficacious and safe oral phosphate binder that controls serum phosphorus, increases iron stores as measured by serum ferritin and TSAT, and reduced the use of IV iron and ESAs, while sustaining hemoglobin as compared to the active control group. ZenerexZerenex met the pre-defined primary and key secondary endpoints for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis. The Full Research Report on Keryx Biopharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [ http://www.WSReports.com/r/full_research_report/27d7_KERX]

--

Pacira Pharmaceuticals ,  Inc. Research Report

On May 29, 2013, Pacira Pharmaceuticals, Inc. (Pacira) announced the findings from the completed first part of its Phase 2/3 clinical trial for the assessment of the use and administration of Exparel (bupivacaine liposome injectable suspension) as a single-dose injection femoral nerve block for total knee arthroplasty surgery (TKA). Dave Stack, President and CEO of Pacira, stated, "We are pleased with the interim analysis of the safety and efficacy of EXPAREL in this important orthopedic indication." Stack continued, "Based on the independent Data Safety Monitoring Board analysis, we believe that a single-dose injection of EXPAREL as a femoral nerve block can provide several days of analgesia without significant motor blockade. We look forward to initiating the Phase 3 portion of this trial and ultimately to providing orthopedic patients with a new option that could significantly contribute to the management of their postsurgical pain by replacing a perineural catheter, drug reservoir and pump with a single-dose injection of EXPAREL." The Full Research Report on Pacira Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [ http://www.WSReports.com/r/full_research_report/c8a5_PCRX]

----

2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs